---
layout: default
title: Ceftobiprole
parent: Model Prediction Only (L5)
nav_order: 166
evidence_level: L5
indication_count: 10
---

# Ceftobiprole
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ceftobiprole: From Antibacterial Therapy to Rheumatoid Arthritis

## One-Sentence Summary

Ceftobiprole is a cephalosporin antibiotic marketed in Canada as ZEVTERA. It works by inhibiting bacterial cell-wall synthesis, including in MRSA.
The TxGNN model predicts it may be effective for **Rheumatoid Arthritis**, but **0 clinical trials** and **0 publications** currently support this direction. The prediction is model-only and should be treated as a likely artifact.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in the available Canadian licence data. Ceftobiprole is a beta-lactam antibacterial. |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 98.45% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the record. From general pharmacology, ceftobiprole is a beta-lactam cephalosporin. It inhibits bacterial penicillin-binding proteins (PBPs), including PBP2a in MRSA. Its established use is against bacterial infections.

**A plausible mechanistic link to rheumatoid arthritis is not evident.** Rheumatoid arthritis is an autoimmune synovitis. Ceftobiprole has no known immunomodulatory or anti-inflammatory action relevant to it. The high TxGNN score (98.45%) comes from the knowledge graph alone. It may reflect graph-neighbourhood artifacts rather than real biology.

The other top-ranked predictions show the same pattern:

- **Joint and inflammatory conditions:** osteoarthritis, osteoarthritis susceptibility and gout.
- **Rare skeletal dysplasias:** pseudoachondroplasia, brachyolmia and Hunter-Thompson type acromesomelic dysplasia.
- **Other rare disorders:** hemoglobinopathy, myosclerosis and colobomatous microphthalmia-rhizomelic dysplasia syndrome.

All ten predictions are L5 with no trials or literature. Many of these targets are genetic or degenerative conditions with no antibacterial rationale. Together this suggests a systematic graph-proximity effect, not drug-specific signals.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2446685 | ZEVTERA | Not listed | Not listed |

---

## Safety Considerations

Please refer to the package insert for safety information. No drug-interaction records were found for this drug.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a model score, with no trials, no publications and no plausible mechanistic link between a PBP-targeting antibacterial and rheumatoid arthritis. Safety information is also missing, so the candidate cannot advance past the initial screening stage.

**To proceed, the following is needed:**
- Health Canada product monograph (warnings and contraindications) for ZEVTERA
- Confirmed mechanism of action data from DrugBank
- Preclinical or mechanistic evidence of an anti-inflammatory or immunomodulatory effect in synovitis models
- Route and formulation compatibility assessment (ceftobiprole's approved route is not stated in the data received)
- Any published or registered studies of ceftobiprole in rheumatoid arthritis, if they exist

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

